(Z)-endoxifen (endoxifen) is the active metabolite of tamoxifen. Endoxifen is a potent antiestrogen that binds and blocks estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ). Early-phase clinical trials have shown that endoxifen has promis...
Target identification in natural products plays a critical role in the development of innovative drugs. Bufalin, a compound derived from traditional medicines, has shown promising anti-cancer activity; however, its precise molecular mechanism of acti...
BACKGROUND: Although the clinical outcome of ER + breast cancer patients receiving tamoxifen after surgery is favorable, a proportion of patients experience recurrence or death due to disease progression.
Objective Endometrial lesions are a frequent complication following breast cancer, and current diagnostic tools have limitations. This study aims to develop a machine learning-based nomogram model for predicting the early detection of endometrial les...
European journal of cancer (Oxford, England : 1990)
Dec 21, 2017
BACKGROUND: Prior randomised controlled trials on adjuvant hormonal therapy included HER2 patients; however, a differential effect of aromatase inhibitors (AIs) versus tamoxifen (TAM) may have been missed in ER+/HER2+ patients that comprise 7-15% of ...
BACKGROUND: Efficiently discovering low risk drugs is important for drug development. However, the heterogeneity in patient population complicates the prediction of the therapeutic efficiency. Drug repositioning aiming to discover new indications of ...
European review for medical and pharmacological sciences
Dec 1, 2024
OBJECTIVE: CYP2D6 plays a critical role in metabolizing tamoxifen into its active metabolite, endoxifen, which is crucial for its therapeutic effect in estrogen receptor-positive breast cancer. Single nucleotide polymorphisms (SNPs) in the CYP2D6 gen...
Journal of the National Cancer Institute
Dec 1, 2017
BACKGROUND: Aromatase inhibitors (AIs) are given as adjuvant therapy for hormone receptor-positive breast cancer in postmenopausal women, also to those with chemotherapy-induced ovarian function failure. The current analysis reports on endocrine data...
There has been an increase in deaths from cardiovascular diseases following breast cancer therapy. Evidence has shown that this outcome is, in part, associated with cardiotoxicity induced by the chemotherapeutic drugs and the increase in oxidative st...
Breast cancer is the most commonly diagnosed cancer among women, but despite survival rates improvement, it is still the second major cause of cancer related death. In postmenopausal women with estrogen receptor (ER) dependent breast cancer, hormone ...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.